← Back to Search

Aerosolized Tobramycin or Vancomycin for Ventilator-Associated Pneumonia (AAINTVAP Trial)

Phase 4
Waitlist Available
Led By John K. Bini, MD
Research Sponsored by Wright State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical Pulmonary Infection Score (CPIS) greater than or equal to 6
Intubated greater than or equal to 48 hours
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9-21 days after initiating antibiotic therapy
Awards & highlights

AAINTVAP Trial Summary

The purpose of this study is to determine if administering inhaled antibiotics directly into the lungs in conjunction with intravenous (IV) antibiotics leads to better outcomes and decreased recurrence of ventilator associated pneumonia (VAP) when compared to IV antibiotics alone.

Eligible Conditions
  • Ventilator-Associated Pneumonia

AAINTVAP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

AAINTVAP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9-21 days after initiating antibiotic therapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9-21 days after initiating antibiotic therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Persistence of Pneumonia
Recurrence of Pneumonia
Secondary outcome measures
28-day ICU Mortality
Emergence of Resistant Organisms
Intensive Care Unit (ICU) -Free Days in 28 Days
+4 more

AAINTVAP Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Aerosolized Tobramycin or VancomycinExperimental Treatment1 Intervention
Aerosolized tobramycin 300 mg diluted in 5 mL 0.9% normal saline q.12h. Aerosolized vancomycin 125 mg diluted in 5 mL 0.9% normal saline q.8h.
Group II: Aerosolized PlaceboPlacebo Group1 Intervention
Placebo tobramycin 0.5 mL 0.9% normal saline q.12h. Placebo vancomycin 0.5 mL 0.9% normal saline q.8h.

Find a Location

Who is running the clinical trial?

Wright State UniversityLead Sponsor
41 Previous Clinical Trials
54,866 Total Patients Enrolled
Priti Parikh, PhDStudy DirectorWright State University
John K. Bini, MDPrincipal InvestigatorWright State University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
American Review of Respiratory DiseaseJournal
Diagnosis of Ventilator-associated Pneumonia by Bacteriologic Analysis of Bronchoscopic and Nonbronchoscopic “blind
Pugin, Jérôme, Raymond Auckenthaler, Nabil Mili, Jean-Paul Janssens, P. Daniel Lew, and Peter M. Suter. 1991. “Diagnosis of Ventilator-associated Pneumonia by Bacteriologic Analysis of Bronchoscopic and Nonbronchoscopic “blind” Bronchoalveolar Lavage Fluid”. American Review of Respiratory Disease. American Thoracic Society. doi:10.1164/ajrccm/143.5_pt_1.1121.
clinicaltrials.govStudy
Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia
John Bini 2015. "Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02478710.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top